Literature DB >> 19293004

Autoimmune neutropenia in adults.

Mojtaba Akhtari1, Brian Curtis, Edmund K Waller.   

Abstract

Autoimmune neutropenias (AIN) in adults are a heterogeneous group of diseases with clinical manifestations varying from being asymptomatic to having infectious complications with considerable morbidity and mortality. They are characterized by autoantibodies directed against neutrophils, resulting in destruction of neutrophils. AIN can be divided into two forms. In primary AIN, neutropenia is usually the sole hematologic abnormality and it is more common in children. Secondary AIN, which is more prevalent in adults, is associated with underlying autoimmune diseases, malignancies, infections, particularly viral, neurological diseases or drug exposure. This article is an overview of these conditions with emphasis on secondary AIN; it also discusses the available serological methods for antibody detection and recent therapeutic developments including colony stimulating factors, rituximab and Campath-1H.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293004     DOI: 10.1016/j.autrev.2009.03.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  26 in total

1.  The frequency and specificity of human neutrophil antigen antibodies in a blood donor population.

Authors:  Jerome L Gottschall; Darrell J Triulzi; Brian Curtis; Ram M Kakaiya; Michael P Busch; Philip J Norris; Simone A Glynn; Danielle Carrick; David J Wright; Steve Kleinman
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

2.  Adult-onset autoimmune neutropenia with antineutrophil antibodies to an unknown neutrophil-specific antigen analyzed by using five cell-lineage immunofluorescence test and reactivity against cell lines expressing human neutrophil antigens.

Authors:  Masatoshi Nishizawa; Fumiya Hirayama; Nobuki Matsuyama; Noriko Sugino; Mitsuru Tsudo
Journal:  Int J Hematol       Date:  2010-07-22       Impact factor: 2.490

3.  Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report.

Authors:  Mariam Rauf; Charise Gleason; Ajay K Nooka; Abbie Husman; Edmund K Waller
Journal:  J Med Case Rep       Date:  2011-08-12

4.  The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia.

Authors:  Abdulgabar Salama; Dirk Hartnack; Hans-Walter Lindemann; Hans-Joachim Lange; Mathias Rummel; Andreas Loew
Journal:  Transfus Med Hemother       Date:  2014-09-15       Impact factor: 3.747

5.  Combined IgG4κ and IgG1λ deposition in the glomerular and tubular basement membrane accompanied by autoimmune neutropenia (AIN) and immune thrombocytopenia (ITP).

Authors:  Chiari Kojima; Kazuho Honda; Ari Shimizu; Takahito Moriyama; Hidekazu Sugiura; Mitsuyo Itabashi; Takashi Takei; Sekiko Taneda; Takashi Ehara; Kosaku Nitta
Journal:  CEN Case Rep       Date:  2015-02-26

6.  Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease.

Authors:  Martina M McGrath; Tamara Isakova; Helmut G Rennke; Ann M Mottola; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 8.237

Review 7.  An update on the diagnosis and treatment of chronic idiopathic neutropenia.

Authors:  David C Dale; Audrey A Bolyard
Journal:  Curr Opin Hematol       Date:  2017-01       Impact factor: 3.284

8.  Autoimmune cytopenias and thrombotic thrombocytopenic purpura.

Authors:  Charlotte K Brierley; Sue Pavord
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

9.  Clinical applications of immunoglobulin: update.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.

Authors:  Kazuyo Nagashima; Hiroaki Tanaka; Yurie Nagai; Yasumasa Sugita
Journal:  BMJ Case Rep       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.